Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 19/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.64 |
| ▸ | NPY1R | P25929 | 10/20 | 0.64 |
| ▸ | NPY2R | P49146 | 7/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036458 | 0.94 | NPY4R (0.66) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL2632460 | 0.91 | NPY4R (0.71) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16273801 | 0.81 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL28474284 | 0.81 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL18797119 | 0.80 | NPY4R (0.49) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL27433212 | 0.79 | NPY4R (0.46) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL23230088 | 0.79 | NPY4R (0.66) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22380026 | 0.78 | NPY4R (0.43) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL23106000 | 0.77 | NPY4R (0.45) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL19681343 | 0.77 | NMT1 (0.46) | NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642555-B2 | Prodrugs | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20120094892-A1 | PRODRUGS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094892-A1 | PRODRUGS | ACP3, KLK3, FOLH1 | NPY4R 4470/4885NPY5R 3918/4885NPY1R 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.